Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
NSAID-induced Gastroduodenal InjuryUlcersRheumatoid ArthritisOsteoarthritis
Interventions
DRUG

Cobiprostone

18 mcg cobiprostone capsules for oral administration

DRUG

Placebo

Matching placebo capsules for oral administration

DRUG

Non-steroidal anti-inflammatory drug

Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.

Trial Locations (19)

10021

Research Associates of New York, New York

11023

Long Island Gastrointestinal Research Group, Great Neck

16635

Altoona Center for Clinical Research, Duncansville

19140

Gastroenterology Section at Temple University Hospital, Philadelphia

23502

Digestive and Liver Disease Specialists, Norfolk

27599

University of North Carolina Gastroenterology, Chapel Hill

33024

University Clinical Research, Inc., Pembroke Pines

60612

University of Illinois Medical Center, Chicago

70808

Gulf Coast Research, LLC, Baton Rouge

73104

Oklahoma Founddation for Digestive Research, Oklahoma City

75216

Dallas VA Research Corporation, Inc., Dallas

77074

Houston Institute for Clinical Research, Houston

85012

Carl T Hayden VA Medical Center, Phoenix

91343

Sepulveda Ambulatory Care Center, Sepulveda

91345

Facey Medical Foundation, Mission Hills

91910

Gregory J. Wiener, MD PC, Chula Vista

92262

Desert Oasis Healthcare, Palm Springs

92354

Loma Linda University Physicians Medical Group, Loma Linda

02118

Boston Medical Center, Boston

All Listed Sponsors
lead

Sucampo Pharma Americas, LLC

INDUSTRY

NCT00597818 - Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury | Biotech Hunter | Biotech Hunter